Surprisingly, CD24Fc not only preserve cancer therapeutic effect of anti-CTLA-4 and anti-PD-1 antibodies, but promoted tumor rejection in some cancer models, concurrent with reducing the frequency of regulatory T cells among CD4 cells and preventing exhaustion of CD8 T cells in the tumor microenvironment (45). This evidence concerns the gene CTLA4 and neoplasm.